These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37258256)

  • 21. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.
    Scott MR; Hampton OL; Buckley RF; Chhatwal JP; Hanseeuw BJ; Jacobs HI; Properzi MJ; Sanchez JS; Johnson KA; Sperling RA; Schultz AP
    Neuroimage; 2020 Oct; 220():116991. PubMed ID: 32512123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Schöll M; Ossenkoppele R; Strandberg O; Palmqvist S; ; Jögi J; Ohlsson T; Smith R; Hansson O
    Brain; 2017 Sep; 140(9):2286-2294. PubMed ID: 29050382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multi-Dimensional Comparison of Alzheimer's Disease Neurodegenerative Biomarkers.
    Liu Y; Han PR; Hu H; Wang ZT; Guo Y; Ou YN; Cao XP; Tan L; Yu JT;
    J Alzheimers Dis; 2022; 87(1):197-209. PubMed ID: 35275546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
    JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased salivary lactoferrin levels are specific to Alzheimer's disease.
    González-Sánchez M; Bartolome F; Antequera D; Puertas-Martín V; González P; Gómez-Grande A; Llamas-Velasco S; Herrero-San Martín A; Pérez-Martínez D; Villarejo-Galende A; Atienza M; Palomar-Bonet M; Cantero JL; Perry G; Orive G; Ibañez B; Bueno H; Fuster V; Carro E
    EBioMedicine; 2020 Jul; 57():102834. PubMed ID: 32586758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for neurodegenerative diseases.
    Hansson O
    Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frontal variant of Alzheimer's disease with asymmetric presentation mimicking frontotemporal dementia: Case report and literature review.
    Li CH; Fan SP; Chen TF; Chiu MJ; Yen RF; Lin CH
    Brain Behav; 2020 Mar; 10(3):e01548. PubMed ID: 31989779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
    Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
    JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
    Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
    JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer.
    Milà-Alomà M; Salvadó G; Shekari M; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; González-de-Echávarri JM; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Suárez-Calvet M; Molinuevo JL
    J Prev Alzheimers Dis; 2021; 8(1):68-77. PubMed ID: 33336227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tau Positron Emission Tomography].
    Higuchi M
    Brain Nerve; 2017 Jul; 69(7):819-823. PubMed ID: 28739996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.